Literature DB >> 15106746

[Left ventricular hypertrophy in hypertensive patients. Epidemiology and prognosis].

J Julien1, C Tranche, T Souchet.   

Abstract

The aim of this review is to analyze the epidemiology and prognosis of left ventricular hypertrophy (LVH) in hypertensive patients through literature data and to identify clinical factors contributing to its development. After an exhaustive review of literature through Medline database, eighteen studies (including 8 European ones) have been selected. The prevalence of LVH diagnosed by EKG (7 studies) is steadily over 15%. It can reach 50% in some subgroups of the Framingham study. Among 11 studies using echocardiography as diagnostic tool, the prevalence varies from 14 to 44% (Bordeaux cohort). In the Framingham study, 32% of men and 45% of women over 60 years presented an echography-defined LVH. The variations observed in different studies may be explained by differences on the modes of enrollment and diagnosis. The clinical factors associated with the occurrence of LVH are age, which can be confounded with the duration of presence of hypertension, the severity and lack of therapeutic management of hypertension. Thirteen studies permitted to quantify the cardiovascular risk related to hypertension. In hypertensive patients, the presence of EKG-LVH or the one observed by echocardiography would correspond to a two-fold increase of cardiovascular mortality and morbidity. Moreover, a cardiovascular risk gradient is observed according to the LVH geometry (concentric remodeling, followed by eccentric LVH and concentric LVH). Three studies including the Framingham study demonstrated that LVH is a major risk factor of stroke. This exhaustive literature review stresses on the high prevalence and the severity of LVH during hypertension. Its diagnosis allows to identify high cardiovascular risk patients suffering from hypertension. It emphasizes on the importance of an early and careful therapeutic management of hypertension.

Entities:  

Mesh:

Year:  2004        PMID: 15106746

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  4 in total

1.  Can a cardiac peptide predict mortality in human hypertension?

Authors:  Valentina Cannone; Paul M McKie; John C Burnett
Journal:  Hypertension       Date:  2011-03-07       Impact factor: 10.190

2.  A mitochondrial mutation A4401G is involved in the pathogenesis of left ventricular hypertrophy in Chinese hypertensives.

Authors:  Hai-Yan Zhu; Shi-Wen Wang; Li Liu; Yan-Hua Li; Rui Chen; Lin Wang; C James Holliman
Journal:  Eur J Hum Genet       Date:  2008-08-13       Impact factor: 4.246

3.  Gallic Acid Reduces Blood Pressure and Attenuates Oxidative Stress and Cardiac Hypertrophy in Spontaneously Hypertensive Rats.

Authors:  Li Jin; Zhe Hao Piao; Simei Sun; Bin Liu; Gwi Ran Kim; Young Mi Seok; Ming Quan Lin; Yuhee Ryu; Sin Young Choi; Hae Jin Kee; Myung Ho Jeong
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

4.  Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy.

Authors:  Xin Li; Hang Zhu; Peng Li; Qian Xin; Jie Liu; Wei Zhang; You-Hong Xing; Hao Xue
Journal:  J Geriatr Cardiol       Date:  2013-09       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.